Cargando…

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML

SIMPLE SUMMARY: Donor lymphocyte infusions (DLIs) are immune cells of the donor. They can potentially directly target leukemic cells. Thus, DLIs can be given to acute myeloid leukemia (AML) patients after allogeneic hematopoietic cell transplantation (alloHCT) in order to prevent or treat relapse. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teich, Katrin, Stadler, Michael, Gabdoulline, Razif, Kandarp, Jyoti, Wienecke, Clara, Heida, Bennet, Klement, Piroska, Büttner, Konstantin, Venturini, Letizia, Wichmann, Martin, Puppe, Wolfram, Schultze-Florey, Christian, Koenecke, Christian, Beutel, Gernot, Eder, Matthias, Ganser, Arnold, Heuser, Michael, Thol, Felicitas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416875/ https://www.ncbi.nlm.nih.gov/pubmed/37568726 http://dx.doi.org/10.3390/cancers15153911

Ejemplares similares

Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up
por: Shahswar, Rabia, et al.
Publicado: (2020)

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
por: Klement, Piroska, et al.
Publicado: (2022)

Healthy-like CD4(+) Regulatory and CD4(+) Conventional T-Cell Receptor Repertoires Predict Protection from GVHD Following Donor Lymphocyte Infusion
por: Schneider, Jessica, et al.
Publicado: (2022)

Clonal expansion of CD8(+) T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI
por: Schultze-Florey, Christian R., et al.
Publicado: (2021)

VH1 Family Immunoglobulin Repertoire Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation
por: Sethi, Maya K., et al.
Publicado: (2017)

(18)F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
por: Derlin, Thorsten, et al.
Publicado: (2020)

IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis
por: Kattih, Badder, et al.
Publicado: (2020)

The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease
por: Stadler, Michael, et al.
Publicado: (2023)

P510: PREDICTORS OF RESPONSE AND OUTCOME IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA RECEIVING VENETOCLAX WITH NON-INTENSIVE CHEMOTHERAPY
por: Krüger, Katja, et al.
Publicado: (2023)

Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow
por: Engel, Nils W., et al.
Publicado: (2020)

Neurological management and work-up of neurotoxicity associated with CAR T cell therapy
por: Möhn, Nora, et al.
Publicado: (2022)

Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse
por: Odak, Ivan, et al.
Publicado: (2022)

Distribution of major lymphocyte subsets and memory T-cell subpopulations in healthy adults employing GLP-conforming multicolor flow cytometry
por: Schultze-Florey, Christian R., et al.
Publicado: (2021)

Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia
por: Sharma, Amit, et al.
Publicado: (2020)

Navigating preemptive and therapeutic donor lymphocyte infusions in advanced myeloid malignancies by high-sensitivity chimerism analysis
por: Stadler, Michael, et al.
Publicado: (2022)

Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia
por: Mohanty, Sagarajit, et al.
Publicado: (2020)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)

Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia
por: Kloos, Arnold, et al.
Publicado: (2020)

Correction: Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia
por: Kloos, Arnold, et al.
Publicado: (2021)

Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy
por: Ravens, Sarina, et al.
Publicado: (2018)

Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative Disease
por: Schultze-Florey, Rebecca E., et al.
Publicado: (2018)

qPIPSA: Relating enzymatic kinetic parameters and interaction fields
por: Gabdoulline, Razif R, et al.
Publicado: (2007)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

On the structure and dynamics of the complex of the nucleosome and the linker histone
por: Pachov, Georgi V., et al.
Publicado: (2011)

Donor Vδ1(+) γδ T cells expand after allogeneic hematopoietic stem cell transplantation and show reactivity against CMV-infected cells but not against progressing B-CLL
por: Prinz, Immo, et al.
Publicado: (2013)

Treatment of Relapsed Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2020)

Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
por: Georgi, Julia-Annabell, et al.
Publicado: (2022)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

Reappearance of effector T cells is associated with recovery from COVID-19
por: Odak, Ivan, et al.
Publicado: (2020)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
por: Panagiota, Victoria, et al.
Publicado: (2023)

webPIPSA: a web server for the comparison of protein interaction properties
por: Richter, Stefan, et al.
Publicado: (2008)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome
por: Thivakaran, Aniththa, et al.
Publicado: (2018)

Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion
por: Feurstein, Simone, et al.
Publicado: (2018)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3konubiaq2qt97r0g9vcpv5n6t